Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company known for its innovative bicyclic peptide (Bicycle®) technology, will be participating in three significant investor conferences in June 2024. These conferences include the Jefferies Global Healthcare Conference on June 5, the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, and the TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit on June 17. Each event will feature a live fireside chat with the company's management team.

Investors can access live webcasts of these chats through the Investor section on Bicycle Therapeutics' website, with replays available post-event.

Positive

• Bicycle Therapeutics' participation in high-profile conferences like Jefferies, Goldman Sachs, and TD Cowen showcases the company's growing visibility and importance in the healthcare sector.
• Live webcasts and archived replays provide accessibility and transparency for investors, potentially boosting investor confidence and engagement.

Negative

• The press release lacks specific financial or clinical data updates, which might be a missed opportunity to provide more in-depth analysis for investors.
• The announcement does not specify any new developments or breakthroughs to be discussed, possibly indicating a period of stagnation or lack of significant news.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle^®) technology, today announced that management will participate in the following investor conferences in June:

• Jefferies Global Healthcare Conference on Wednesday, June 5, 2024; fireside chat at 8:30 a.m. ET
• Goldman Sachs 45^th Annual Global Healthcare Conference on Monday, June 10, 2024; fireside chat at 1:20 p.m. ET
• TD Cowen 2^nd Annual Radiopharmaceutical Innovation Summit on Monday, June 17, 2024; fireside chat at 3:00 p.m. ET

Live webcasts of the fireside chats will be accessible in the Investor section of the Company’s website at www.bicycletherapeutics.com. Archived replays of the webcasts will be available following the fireside chat dates.

About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle^® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle^® Toxin Conjugate (BTC^®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist^® (Bicycle TICA^®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle^® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle^® technology to develop therapies for diseases beyond oncology.

Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240603383416/en/

Investors:

Stephanie Yao

SVP, Investor Relations and Corporate Communications

ir@bicycletx.com

857-523-8544

Media:

Deborah Elson

Argot Partners

media@bicycletx.com

212-600-1902

Source: Bicycle Therapeutics plc

FAQ

What investor conferences is Bicycle Therapeutics attending in June 2024?

Bicycle Therapeutics will attend the Jefferies Global Healthcare Conference on June 5, the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, and the TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit on June 17.

When will the fireside chats for Bicycle Therapeutics take place?

The fireside chats will take place on June 5 at 8:30 a.m. ET, June 10 at 1:20 p.m. ET, and June 17 at 3:00 p.m. ET.

Where can I access the live webcasts for Bicycle Therapeutics' fireside chats?

Live webcasts will be accessible in the Investor section of the Bicycle Therapeutics website, with archived replays available following the chat dates.

What is the significance of Bicycle Therapeutics' participation in these conferences?

Participation in these high-profile conferences enhances Bicycle Therapeutics' visibility and engagement with the investment community.

What is Bicycle Therapeutics known for?

Bicycle Therapeutics is known for its pioneering work with bicyclic peptide (Bicycle®) technology, offering a new class of therapeutics.